Structure-Based Design and Synthesis of Protease Inhibitors Using Cycloalkenes as Proline Bioisosteres and Combinatorial Syntheses of a Targeted Library

Fredrik Thorstensson

Division of Chemistry
Department of Physics, Chemistry and Biology
Linköpings universitet, SE-581 83 Linköping, Sweden

Linköping 2005

Thesis cover art was also on the cover of each issue of the Journal of Medicinal Chemistry beginning July 2003 and continuing through December 2003 with the motivation: The basis for our selection was a combination of esthetics and good science.
Abstract

Structure-based drug design and combinatorial chemistry play important roles in the search for new drugs, and both these elements of medicinal chemistry were included in the present studies. This thesis outlines the synthesis of protease inhibitors against thrombin and the HCV NS3 protease, as well as the synthesis of a combinatorial library using solid phase chemistry. In the current work potent thrombin inhibitors were generated based on the D-Phe-Pro-Arg motif incorporating cyclopentene and cyclohexene scaffolds that were synthesized by ring-closing metathesis chemistry. A structure-activity relationship study was carried out using the crystallographic results for one of the inhibitors co-crystallized with thrombin. HCV NS3 protease inhibitors comprising the proline bioisostere 4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic acid were synthesized displaying low nanomolar activity. The stereochemistry and regiochemistry of the scaffolds were determined by NOESY and HMBC spectra, respectively. The final diastereomeric target compounds were isolated and annotated by applying TOCSY and ROESY NMR experiments. Furthermore, a 4-phenyl-2-carboxy-piperazine targeted combinatorial chemistry library was synthesized to be used early in the lead discovery phase. This was done using a scaffold that was synthesized by palladium-catalyzed aromatic amination chemistry and subsequently derivatized with eight electrophiles and ten nucleophiles.
## Contents

### Contents

List of papers ................................................................................................................................... v

Abbreviations ................................................................................................................................... vii

1 Introduction ...................................................................................................................................... 1

2 Synthesis of a combinatorial library (Paper I) ............................................................................. 3

2.1 Synthesis of the scaffolds ........................................................................................................... 4

2.2 Synthesis of the combinatorial library ........................................................................................ 6

2.3 Purity and yields ........................................................................................................................ 7

2.4 Conclusions ............................................................................................................................... 8

3 Serine proteases ............................................................................................................................. 9

4 Thrombin protease inhibitors (Paper II) ....................................................................................... 12

4.1 The development of thrombin inhibitors based on the D-Phe-Pro-Arg motif ......................... 14

4.2 Synthesis of the scaffolds ......................................................................................................... 17

4.3 The olefin metathesis reaction .................................................................................................. 19

4.3.1 Metathesis trials ................................................................................................................ 22

4.4 Synthesis of the final products ............................................................................................... 24

4.5 Structure-activity relationships ............................................................................................... 27

4.6 Conclusions ............................................................................................................................... 30

5 Inhibitors of the HCV NS3 protease (Paper III) ....................................................................... 31

5.1 Development of NS5A/5B substrate-based inhibitors of the HCV NS3 protease ................. 34

5.2 Synthesis of the scaffold .......................................................................................................... 37

5.2.1 Structure determination of the scaffold using 2D-NMR ..................................................... 39

5.3 Synthesis of the final products ............................................................................................... 41

5.3.1 Chemical stability .............................................................................................................. 45

5.4 Structure determination of the target compounds using 2D-NMR ........................................ 46

5.5 Structure-activity relationships of the final products ............................................................. 50

5.6 Conclusions ............................................................................................................................... 52

6 Acknowledgments ......................................................................................................................... 53

7 References ....................................................................................................................................... 55
List of papers

This thesis is based on the following papers, which are referred to in the text by their Roman numerals:

I. Solid-phase synthesis of libraries generated from a 4-phenyl-2-carboxypiperazine scaffold.


II. Synthesis of Novel Thrombin Inhibitors. Use of Ring-Closing Metathesis Reactions for Synthesis of P2 Cyclopentene and Cyclohexene Dicarboxylic Acid Derivatives.

Fredrik Thorstensson, Ingemar Kvarnström, Djordje Musil, Ingemar Nilsson and Bertil Samuelsson.

III. Synthesis of Novel Potent Hepatitis C Virus NS3 Protease Inhibitors. Discovery of 4-Hydroxy-cyclopent-2-ene-1,2-dicarboxylic Acid as a L-Hydroxyproline Bioisostere in the P2-Position.

Submitted to *J. Med. Chem.*
Abbreviations

BINAP 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl
Boc₂O di-\textit{tert}-butyl dicarbonate
Boc-ON 2-(\textit{tert}-butoxycarbonyloxyimino)-2-phenylacetonitrile
BOP-Cl bis-(2-oxo-3-oxazolidinyl)-phosphinic-chloride
CM cross metathesis
dba dibenzylideneacetone
DCC dicyclohexyl carbodiimide
DCM dichloromethane
DIPEA \(N,N\)-diisopropylethylamine
DMAP 4-dimethylaminopyridine
DMPU \(N,N\)-dimethylpropyleneurea
EC\(_{50}\) median effective concentration (required to induce a 50\% effect in a cell based assay)
EDC \(N\)-(3-dimethylaminopropyl)-\(N\)-ethylcarbodiimide hydrochloride
Fmoc 9-fluorenylmethyl carbamate
Fmoc-ONsu \(N\)-(9-fluorenylmethoxycarbonyloxy)-succinimide
HATU O-(7-azabenzotriazol-1-yl)-\(N,N,N',N'\)-tetramethyluronium hexafluorophosphate
HMBC heteronuclear multiple bond correlation
HMPA hexamethylphosphoramide
HO\(\text{B}t\) 1-hydroxy benzotriazole
HPLC high performance liquid chromatography
HTS high-throughput screening
IC\(_{50}\) inhibitor concentration that causes a 50\% decrease in enzyme activity
LC liquid chromatography
LDA lithium diisopropylamide
MS mass spectroscopy
NHC \(N\)-heterocyclic carbene
NMM \(N\)-methyl morpholine
NOESY nuclear Overhauser effect spectroscopy
Pab \(p\)-amidino benzylamine
p-TsOH \(para\)-toluenesulfonic acid
r.t. room temperature
RCM ring-closing metathesis
ROESY rotational frame Noe spectroscopy
ROM ring-opening metathesis
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAR</td>
<td>structure-activity relationship</td>
</tr>
<tr>
<td>TBTA</td>
<td>tert-butyl 2,2,2-tri-chloooacetimidate</td>
</tr>
<tr>
<td>TES</td>
<td>triethylsilane</td>
</tr>
<tr>
<td>TFA</td>
<td>trifluoroacetic acid</td>
</tr>
<tr>
<td>TFMSA</td>
<td>trifluoromethane sulfonic acid</td>
</tr>
<tr>
<td>TMEDA</td>
<td>$N,N,N',N'$-tetramethylethylenediamine</td>
</tr>
<tr>
<td>TOCSY</td>
<td>total correlation spectroscopy</td>
</tr>
<tr>
<td>UV</td>
<td>ultraviolet</td>
</tr>
<tr>
<td>Z</td>
<td>benzyloxy carbonyl</td>
</tr>
</tbody>
</table>
1 Introduction

Drug discovery is a complex undertaking, and it is not possible to present straightforward simple flowcharts that adequately describe this process. The task includes intricate interplay between biology and chemistry, or more precisely, application of organic chemistry and the more specialized field called medicinal chemistry in combination with biochemical and biological tests (Figure 1.1).

In the target identification step, researchers determine the therapeutic focus, e.g. a specific enzyme or receptor that plays a vital role in the disease or condition in question. Many pathophysiological conditions and disease states are due to over expression or enhanced activity of a specific enzyme, e.g. protease, and this activity can be attenuated by administration of a specific protease inhibitor. In the design of such protease inhibitors one strategy utilizes the knowledge of the natural substrates from which substrate-based protease

![Figure 1.1. The iterative structure based process of designing a new drug.](image)

![Figure 1.2. The development of a candidate drug to a marketable medicine.](image)
inhibitors can be designed ([papers II–III](#)). These molecules mimic the natural substrate of the target, and in most cases the starting point of synthesis is a truncated polypeptide (e.g., a hexapeptide) in which all amino acid positions are systematically varied to gain increased knowledge of SAR, *i.e.*, specificity and selectivity. Another approach that attracted much attention in the 1990s involves the synthesis of large compound libraries (comprising several million members) by the use of combinatorial chemistry. These libraries are tested (screened) against numerous targets utilizing HTS (High Throughput Screening) techniques to deliver active compounds, Hits ([paper I](#)). Promising Hit compounds identified are then subjected to additional *in vitro* tests, and if still promising are optimized by chemical modifications based on the preliminary SAR established (e.g., by synthesis of a new library or some new polypeptides) ([hit to lead identification phase](#)). The goal of this iteration between synthesis and *in vitro* tests is to generate a **lead compound**. A lead compound shall exhibit high affinity for its target, have good metabolism and pharmacokinetic properties and include the basic pharmacophore. The pharmacophore is the correct spatial arrangement of chemical groups necessary to achieve the desired interaction with the target. The basic pharmacophore can be looked upon as a crude blueprint, in other words its structure includes vital features but is far from perfect. Refinements in the Hit-to-Lead phase is greatly aided by X-ray crystal data of an inhibitor in complex with the target protease. In the subsequent **lead optimization** phase the synthesis of new compounds is aided by additional SAR gained from extensive biological testings, and when a compound performs well in all biological tests, it can be nominated to a **candidate drug** and large scale synthesis of the active ingredient is performed before testing in humans can begin (Figure 1.2). In the first stage in human subjects, called **Phase I**, the drug is tested on healthy volunteers, and, if no complications occur, the testing is continued in **Phase II** studies, which include a few hundred patients with the disorder of interest. The last step entails the **Phase III** investigations, which include several thousand patients. If the compound exhibits better clinical properties than drugs that are already on the market, it is time to submit a **new drug application**, and hopefully the novel substance will be approved for clinical use by the appropriate institution (e.g., the Food and Drug Administration (FDA) in the United States). On average, the entire process from selecting a target disease to market analysis and the release of an approved drug takes about 10 to 15 years and costs approximately 8 billion SEK.\(^1\)
2 Synthesis of a combinatorial library (Paper I)

Potential lead compounds can be discovered by synthesizing numerous well-defined combinatorial libraries and then using HTS aimed against many different targets (e.g., HIV protease, thrombin, and HCV NS3 protease). The objective of such screening is hit identification, that is, to discover one or several compounds in the synthesized library that exhibit activity against one of the chosen targets and can hopefully be refined to a lead.

In a project originated at AstraZeneca the generic scaffold $S$ shown in Figure 2.1 was considered to be a therapeutically interesting template that was amenable to library exploration in the lead identification phase. Although members of $S$ already exist that have been shown to display antibacterial and oxytocin receptor-antagonistic activities, scaffold $S$ still represent a interesting framework for pharmaceutical development. From $S$, we selected the two specific scaffolds a and b for synthesis of a small library of drug-like compounds that could be used in biological evaluations in the early lead discovery phase. It is important that such a library follows the empirical “Lipinski’s rule of five” concerning permeation and solubility. It postulates that drug-like molecules should not have more than five hydrogen bond donors or more than 10 hydrogen bond acceptors, nor should they have a molecular weight exceeding 500 g/mol or a calculated Log P value $\geq 5$ in octanol/water. A compound can have good absorptive properties if it meets three of the four criteria, but probably not if it satisfies only one or two. The strategy used to synthesize the library was to prepare the regioisomeric scaffolds 1a and 1b by standard solution-phase chemistry (Scheme 2.1). These scaffolds were subsequently immobilized on a solid phase and combinatorially diversified with eight electrophiles and ten nucleophiles to create a library consisting of $80 \times 2 = 160$ compounds. The solid phase consists of a polymer (resin) with attached linkers to which a scaffold can be coupled, and we chose to use carboxy-activated wang resin (Figure 2.2). Solid-phase chemistry allows time-efficient purification, hence many
compounds can be synthesized. The easy purification procedure, which consists of sequential rinsing of the resin with different solvents, makes it possible to use excessive amounts of reagents (10–30 equivalents) and thereby increase the reaction rates and raise the yields. The drawback of solid-phase chemistry is that commonly employed monitoring techniques, such as TLC and HPLC/MS, can’t be used, and it is instead necessary to perform cleavage of the scaffold followed by solution-phase analyses, or to conduct NMR experiments directly on the resin. This disadvantage is a problem only when trying out the reaction sequence, not when a successful protocol has been worked out.

2.1 Synthesis of the scaffolds

The amino acid 2 was selectively monoprotected with Boc-ON (2-((tert-butoxycarbonyloxyimino)-2-phenylacetonitrile) in dioxane/water, and the pH of the solution was adjusted to 11 with aqueous sodium hydroxide (Scheme 2.1). The pH was then lowered to 9.5 with hydrochloric acid, and Z-Cl (benzyl chloroformate) was added. Thereafter, the diprotected piperazine-2-carboxylic acid was esterified with iodomethane and aqueous sodium bicarbonate under phase-transfer conditions in DCM (dichloromethane), which gave the fully protected piperazine-2-carboxylic acid 3 in 78% yield. The tert-butoxycarbonyl group was cleaved to yield 4 by treating 3 with hydrochloric acid in dioxane. Reacting Z-protected piperazine 4 with o-fluoro-nitrobenzene for five days gave 5a in 95% yield.

Scheme 2.1. Synthesis of scaffolds 1a and 1b.^[1]

---

*a Reagents and conditions: (a) Boc-ON, pH 11, dioxane/H2O 1:1; (b) Z-Cl, pH 9.5; (c) CH3I, NaHCO3 (aq), adogen 464, DCM; (d) HCl, dioxane; (e) 2-fluoronitrobenzene, TEA, 60°C; (f) Pd(OAc)2, BINAP, CsCO3, 3-bromonitrobenzene, toluene, 100 °C ; (g) TFMSA, anisole, DCM.

---
However, as expected, direct nucleophilic aromatic substitution using the corresponding m-fluoro-nitrobenzene was unsuccessful, because the m-nitro substituent has a less prominent deactivating effect. Using the palladium chemistry described below, 5b was synthesized in 78% yield, and Z-deprotection of 5a and 5b using TFMSA (trifluoromethane sulfonic acid) in DCM gave the free amines 1a and 1b in 92% and 85% yield, respectively.

Advances in palladium-catalyzed aromatic aminations achieved by Stephen L. Buchwald and John F. Hartwig over the last decade have enabled chemists to synthesize compounds that can’t be synthesized by direct nucleophilic aromatic substitutions.7,8 There are many viable palladium sources (e.g., PdCl₂, Pd₂(dba)₃, and Pd(Ph₃)₄), and there is also a multitude of different phosphines (e.g., PPh₃, Xantphos, Poto₃ and PBu₃). The catalytic cycle using Pd(OAc)₂ as a source of Pd(0) generated in situ with BINAP as a phosphine ligand is illustrated in Figure 2.3 (Phase 1). The monodentate Pd(0) species achieves an oxidative addition to the aryl bromide, creating the (L)Pd(Ar)(Br) complex (Phase 2). The amine coordinates to the (L)Pd(Ar)(Br) complex (Phase 3), and the addition of base facilitates deprotonation of the amine and elimination of the bromide to generate the amido complex.

**Figure 2.3.** The catalytic cycle for the palladium-catalyzed aromatic aminations.
(L)Pd(Ar)[NR(R')] (Phase 4). This complex is decomposed through reductive elimination to yield the target compound (ArN(R)R’) and the regenerated phosphine-palladium complex (Phase 5).

2.2 Synthesis of the combinatorial library

The scaffolds 1a and 1b were immobilized on the p-nitrophenyl-carbonate-activated Wang resin using DIPEA (N,N'-diisopropylethylamine) in DMF (dimethylformamide) (Scheme 2.2). The loading (81% for 6a and 61% for 6b) was rewarding, considering the poor nucleophilicity of the N1 of piperazine-2-carboxylates. The practical loading was determined by cleavage of a weighed sample of resin followed by analysis on HPLC-UV calibrated with

**Scheme 2.2.** Solid-phase chemistry.\(^a\)

\(^a\) Reagents and conditions: (a) p-nitrophenyl carbonate Wang resin, DIPEA, DMF, 80 °C (b) SnCl\(_2\)·H\(_2\)O, DMF; (c) Chemset 8 (R\(_3\)XCl, X = SO\(_2\) or CO), pyridine, DCM; (d) TMSOK, THF; (e) Chemset 11 (NHR\(_4\)R\(_5\)), PyBOP, NMM, DMF; (f) TFA, 30% in DCM.

**Figure 2.5.** The electrophiles in chemset 8.

**Figure 2.6.** The nucleophiles in chemset 11.
known solutions of scaffolds. Longer reaction times did not improve the loading. Several methods have been reported for reduction of nitro compounds on solid support. Addition of SnCl₂·H₂O in DMF to 6a and 6b resulted in a clean reduction to the anilines 7a and 7b, with no resin cleavage. Premature cleavage of the Wang linker has been reported using SnCl₂·H₂O due to formation of hydrogen chloride and/or Sn(IV) with Lewis acid capabilities. The scaffold 7a was transferred to 80 reservoirs (A–H, 1–10) placed in a rack as shown in Figure 2.4, and 7b was transferred to a similar rack. The first diversification of the library was done by adding the electrophiles from chemset 8 in DCM/pyridine to the rows (A–H) in the two racks, which furnished 8 x 2 = 16 different compounds (Figure 2.5). The resulting set of esters 9a and 9b were hydrolyzed to the corresponding carboxylic acids 10 using potassium trimethylsilanolate in THF (tetrahydrofuran). The second diversification of the library was achieved by coupling the amines in chemset 11 to the free acids 10a and 10b using pyBOP (benzotriazol-1-yl-oxytrityrrolidino-phosphonium hexafluorophosphate) and NMM (N-methyl morpholine) in DMF; this yielded the amides 12a and 12b (Figure 2.6). The amines in chemset 11 were added to the columns (1–10) in the two racks, which gave 80 x 2 = 160 different compounds. The immobilized target compounds were cleaved from the resin with 40% TFA (trifluoroacetic acid) in DCM to provide the desired library consisting of the TFA salts 13a and 13b.

2.3 Purity and yields

Every library member was analyzed by HPLC/MS, and all contained a molecular ion consistent with the expected compound. To further enhance the quality of the library, 39 compounds were subjected to preparative HPLC purification with mass-triggered fraction collection. The purity was greater than 70% for 134 of 160 of the library members and was in no case less than 40%; the average purity was 82%. Notably, almost all of the impurities could be identified by their mass. The most prominent impurities were identified as molecules with a mass 106 or 212 g/mol greater than expected. A plausible explanation for this is that, during the cleavage of chemset 12, some of the Wang linker was liberated as p-hydroxy benzyl cation, which may have been added to the members of 13 by electrophilic substitution. In accordance with that, chemset 13b (20% impurities), which was more prone to electrophilic aromatic substitution than chemset 13a (8% impurities), also contained a larger amount of this impurity.
The average overall yields from the immobilization of the scaffolds to the cleavage of the target compounds from the resin (1a/1b →→→ 13a/13b, Scheme 2) were 61% and 50%, respectively. The yields were calculated based on NMR integrals calculations using hexamethyldisiloxane as internal standard.

2.4 Conclusions

Piperazine-2-carboxylic acid was orthogonally protected and coupled with 2-fluoronitrobenzene and 3-bromonitrobenzene by direct aromatic substitution and palladium-coupled amination, respectively. The two nitrophenyl-piperazine scaffolds were immobilized on solid support and combinatorially derivatized with 8 electrophiles and 10 nucleophiles to yield a library of 160 compounds with an average purity of 82%. The synthesized screening library of 13a and 13b contains the 4-phenyl-2-carboxy-piperazine pharmacophore, which is known to possess antibacterial and oxytocin receptor-antagonistic activities. The methodology used is well adapted for creating larger libraries, and it may be possible to develop a lead from these compounds.
3 Serine proteases

The second part of the thesis (papers II–III) describe the design and synthesis of inhibitors of the two serine proteases thrombin (paper II) and HCV NS3 (paper III). Thrombin regulates the clotting ability of the blood, and inhibiting this protease should decrease the risk of formation of unwanted blood clots that can block narrowed veins and cause a stroke or a heart attack. In patients infected with the hepatitis C virus (HCV) the NS3 protease of the virus is responsible for cleaving the viral polyprotein into smaller active proteins, thus inhibiting NS3 will prevent the assembly of new viruses.

Proteases regulate a wide array of biological responses, for instance they are vital in the replication phase of many viruses and parasites (e.g., HIV and HCV, and the microorganisms that cause malaria), and they also play important roles in the human body by participating in activities such as immune responses, blood coagulation, digestion, and fertilization. Proteases catalyze the hydrolytic cleavage of proteins into smaller peptide fragments by promoting cleavage of certain amide bonds. These enzymes are divided into four major classes called the serine, aspartic, cysteine and metallo proteases, and they all cleave amide bonds to release a carboxylic acid (N-terminal) and an amine (C-terminal) part of the substrate (Figure 3.1). In a protease-substrate complex, the first substituent in the N-terminal direction from the scissile bond is called P1, the second is called P2, and so on; the first substituent in the C-terminal direction is called P1’, the second P2’, and so on (Figure 3.1).13 Correspondingly, the subsites in the enzyme that these Pn or P’n’ substituents interact with are designated S1 or S1’, S2 or S2’, and so on. Proteases in the same family can be divided into subfamilies, and the proteases in the subfamilies are often very similar, therefore is it extremely important to design inhibitors that are highly selective for one particular protease, unless the objective is to inhibit all the proteins in a subfamily. Thrombin and HCV NS3 are both chymotrypsin-like serine proteases. The serine proteases are made up of a catalytic triad (i.e., aspartic acid, histidine, and serine) and an oxyanion hole, and in chymotrypsin-like proteases the latter

![Figure 3.1](image-url)
consists of the peptide backbone of the same serine as in the catalytic triad and the backbone of a glycine in proximity. The catalytic triad cleaves the amide bond, and the oxyanion hole stabilizes the high-energy tetrahedral intermediates. In Figure 3.2, the amino acids are numbered as in the actual chymotrypsin protease; of course the numbers differ for different proteases, and the specific amino acids in the oxyanion hole may also vary in different serine proteases. The hydroxyl group of the serine in the catalytic triad, Ser195 is highly nucleophilic due to hydrogen bonding to the electron-rich His57 (A). The imidazole ring in His57 is rich in electrons as the result of hydrogen bonding to the deprotonated carboxylic acid group in Asp102. The substrate interacts with the protease, whereupon the scissile bond is moved into the active site (B) and the carbonyl group of the scissile bond becomes more electropositive, because it forms a hydrogen bond network with the amino acids in the oxyanion hole. The electropositive carbonyl is attacked by Ser195, which leads to formation of a high-energy oxyanion tetrahedral intermediate that is stabilized in the oxyanion hole (C). The tetrahedral intermediate collapses and the C-terminal cleavage product (the amine) is

![Diagram of the mechanism of serine proteases](image)

**Figure 3.2.** The mechanism of serine proteases.
released, while whereas the carboxylic acid part remains covalently bound to the enzyme through the serine (D). The imidazole ring in His57 forms a hydrogen bond with a water molecule and thereby makes it more nucleophilic (E). The water molecule subsequently makes a nucleophilic attack on the carbonyl, and, for the second time, an oxyanion tetrahedral intermediate is formed (F). The tetrahedral intermediate collapses, and this time the N-terminal cleavage product (the carboxylic acid) is released from the enzyme, and the protease is ready for another catalytic round (A).
Thromboembolism has long been recognized as a major health problem in the Western world, and it entails the unwanted presence or formation of a blood clot (thrombus) (Figure 4.1). If such a clot is dislodged and moves through the blood stream, it is called an Embolus. A blood clot that become lodged in a narrowed blood vessel and block circulation, can lead to life-threatening conditions as stroke (CT and CE) and heart attack (AT). Thrombi can also arises in the knees (DVT), where they can block veins and cause morbidity, or dislodge as emboli and induce morbidity in the lungs (PE). In the United States, one death due to stroke occurs every 3.3 minutes, and about 70–80% of such mortality is caused by CT or CE.14 Around 600,000 people develop PE annually in that country, and 60,000 of those individuals die from the condition. Furthermore, about two million Americans are hit by DVT each year, and roughly five in 1,000 Caucasians have a heart attack (AT). Anticoagulant treatment is given to approximately 0.7% of the population in the western world today, even though the traditional anticoagulant drugs have several drawbacks.15 At present, warfarin and other coumarins are the only such agents that can be administered orally. However, their anticoagulant effects can be erratic as a result of frequent drug–drug and food–drug interactions, which means that patients need to avoid concomitant medication and maintain a well-controlled diet. In addition, there is a narrow therapeutic window (small difference between safe and effective concentrations).16 The low-molecular-weight heparins provoke a more predictable response, but some patients develop immune reactions to those substances.17 Nonetheless, due to their substantial molecular size, heparins must be administered subcutaneously, which tends to
hinder long-term outpatient use. Clearly, there is a strong medical need for a novel, well-tolerated oral anticoagulant with a wide therapeutic window. Many large pharmaceutical companies are now searching for such a drug, and the first to be approved will no doubt achieve blockbuster status (over 1 billion US dollars in revenue).

Coagulation per se is a vital process in that it prevents the harmful loss of blood from injured vessels and a blood clot, whether desired or not, is regulated by the coagulation cascade. In short, this cascade is initiated when damage to epithelial surfaces or some form of trauma triggers a cascade of biological responses that eventually converge in the cleavage of the zymogen prothrombin through factor Xa, which generates the serine protease thrombin (Figure 4.2). Thrombin cleaves off the fibrinopeptides A and B from fibrinogen, which is thereby transformed into fibrin. The fibrin monomers are cross-linked (mediated by factor XIIIa) and aggregate to produce a network that traps platelets and erythrocytes, resulting in formation of a blood clot.

The widely used anticoagulant warfarin inhibits the synthesis of vitamin K, which is necessary for the production of prothrombin. The heparins activate antithrombin, which is the natural inhibitor of thrombin. Since thrombin is one of the key enzymes in the coagulation cascade, it has long been looked upon as a viable drug target for preventing thromboembolism. A sort of proof that the concept of using thrombin inhibitors as drugs is actually feasible is provided by the fact that the saliva of medicinal leeches contains the thrombin inhibitor hirudin (a peptide comprising 65 amino acids). It is believed that the direct inhibition of thrombin will lower the level of fibrin in the blood stream, which will decrease the formation of thrombi and thereby reduce the risk of thromboembolism.

Figure 4.2. A simplified schematic representation of the blood coagulation cascade. Therapeutic anticoagulants are in bold type.
4.1 The development of thrombin inhibitors based on the D-Phe-Pro-Arg motif

In the mid 1950s, Bettelheim showed that thrombin, similar to many other enzymes, is feedback inhibited, and in this case the effect involves the cleavage product fibrinopeptide A, which is a competitive inhibitor of the reaction between thrombin and fibrinogen.\(^{18}\) This finding was the starting point for development of the substrate-based thrombin inhibitors. In the late 1960s, Blombäck and coworkers at the Karolinska Institute proposed that fibrinopeptide A (16 amino acids, \(\text{H}_2\text{N-}\text{Ala-Asp-Ser-Gly-Glu-Asp-Phe-Leu-Ala-Glu-Gly-Gly-Gly-Val-Arg-COOH}\)) has an ordered (\(\alpha\)-helical) structure that position the P9-Phe in space very close to the P2-Val.\(^{19}\) That suggestion was confirmed by NMR studies at the end of the 1980s, and soon thereafter the a X-ray structure of fibrinopeptide A in complex with \(\alpha\)-thrombin was reported.\(^{20}\) Moreover, in the late 1970s, optimizations performed by Bajusz et al. resulted in the synthesis of the aldehyde tripeptide D-Phe-Pro-Arg-H.\(^{21}\)

Our research group in Linköping has worked in collaboration with investigators at AstraZeneca to design and synthesize thrombin inhibitors based on the X-ray crystal structure of the covalently bound inhibitor PPACK (D-Phe-Pro-Arg-CH\(_2\)Cl) in complex with \(\alpha\)-thrombin (Figure 4.3, left).\(^{22,23}\) The irreversible protease inhibitor PPACK is itself not suitable as a drug, because the electrophilic \(\alpha\)-chloroketone moiety can bind covalently to countless nucleophiles en route to the intended target, which gives unwanted side effects. PPACK has been used as a tool to map essential structure-activity relationships (SARs) that can be incorporated into reversible inhibitors. The motif D-Phe-Pro-Arg has been used as a lead identification template for reversible inhibitors, which has resulted in the synthesis of several

**Figure 4.3.** Diagrams showing interactions between PPACK (IC\(_{50}\) 0.017 nM) and thrombin (left), along with melagatran (IC\(_{50}\) 4.7 nM), which is the active substance in the AstraZeneca investigational drug Exanta™. (right).
thrombin inhibitors.\textsuperscript{24,25} A proof of concept of this design strategy is the AstraZeneca drug Exanta\textsuperscript{TM}, which contains the active ingredient melagatran and is now on the market in some countries (Figure 4.3, right).

Fibrinogen is the natural substrate of thrombin, and, like all human enzymes, it consists solely of L-amino acids. In the D-Phe-Pro-Arg motif, the phenylalanine moiety has D-stereochemistry, thus the phenyl moiety in D-Phe has a different vector then the P3 group of the substrate. The D-Phe is directed away from the true S3 pocket and is instead guided into a distal (D) pocket. As mentioned above, it is probably the P9-Phe of fibrinopeptide A that occupies that space in the fibrinopeptide A/\alpha-thrombin complex. Nonetheless often the S3 terminology are used, but that is wrong. According to the nomenclature for thrombin inhibitors generated using the D-Phe-Pro-Arg motif, the P3 group fits in the D pocket, the P2 group interacts with the S2-pocket (also called the proximal (P) pocket), and the P1 group occupies the S1 pocket (also called the specificity pocket). Figure 4.3 shows a two-dimensional (2D) map of PPACK and its interaction with thrombin, and it can be seen that thrombin has an essentially hydrophobic D pocket that is formed by the amino acids Leu99, Trp215, and Ile174. The S2 pocket is also hydrophobically flanked by the amino acids Tyr60A and Trp60D, and situated in the bottom of the deep S1 pocket is the acidic Asp189. Also of interest in the 2D structure are the hydrogen bonding interactions with the backbones of Gly216 and Ser214. The approach used most often in P1 design is to create an ionic bond between the inhibitor and Asp189, and, in both the D-Phe-Pro-Arg motif and PPACK, the guanidino group in Arg constitutes such a bridge. In the early 1990s, researchers at AstraZeneca used what was at that time a new method of computer-assisted design and discovered that the more constrained and rigid \textit{p}-amidino benzylamine (Pab) group was an even better P1 moiety than the Arg.\textsuperscript{26} The Pab group indeed enhanced the overall activity and was used in melagatran, which is the active substance in the prodrug Exanta\textsuperscript{TM}. In melagatran, the P2-Pro and the P3-D-Phe have been replaced with azetidine and a D-cyclohexyl amino acid, respectively. Despite these replacements the structural similarities with the motif (D-Phe-Pro-Arg) are still pronounced. The collaboration between AstraZeneca and Linköping University has led to development of several different thrombin inhibitors that were
synthesizied using the D-Phe-Pro-Arg motif as template (Figure 4.4). In all these compounds, the P1-Arg has been substituted with the para-amidino benzylamine (Pab) group, the P2-proline has been replaced with various proline isosteres, and the P3-D-Phe has been replaced with different amines. In a previous study, the activity of inhibitor 14{4} (970 nM) was promising (Figure 4.5). A comparison of the D-Phe-Pro-Arg motif and 14{4} reveals the following structural similarities: the Pab group is an Arg bioisose, the cyclopentene is a proline bioisostere, and the N-ethyl aniline group is a D-Phe bioisostere. (Figures 4.4 and 4.5).

Paper II describes an optimization study of the lead compound 14{4}, and it also discusses attempts to compare and rationalize the activity of the different cyclopentene isomers in series 14, 31 and 32, and to compare and explain the cyclohexenes in series 17 and the cyclopentenes in series 14 (Figure 4.5). A total of 35 target compounds were synthesized, and the most active of those, 14{22}, had an IC50 of 49 nM (Figure 4.5).

Figure 4.5. The lead compound 14{4} (970 nM); the target compounds in the series 14, 17, 31 and 32; the optimized inhibitor 14{22}. 
4.2 Synthesis of the scaffolds

The scaffold 15 was the key intermediate in the synthesis of the final products in series 14, and the previously used synthetic pathway to the racemic proline isostere 15 involved five steps and gave an overall yield of 12% (Figure 4.6). In short, the target compounds in series 14 were synthesized from scaffold 15 by amide couplings. The carboxylic acid 15 was synthesized from the aldehyde 20 through methylester protection followed by oxidation. The aldehyde 20 was obtained from the hydrolysis of the bicyclic compound 19, which was synthesized by adding dichloroacetyl chloride to cyclopentadiene (produced by retro-Diels-Alder reaction of the dicyclopentadiene 18).

![Figure 4.6. The previously reported retrosynthetic route to the target compounds in series 14.](image)

We were intrigued by a novel and versatile synthetic pathway, which, in addition to yielding 14, facilitated synthesis of the six-membered analog 17 (Figure 4.7). This new route took into account that these compounds are olefins. Over the past few years, olefin metathesis has emerged as a powerful novel carbon-carbon bonding technique (Section 4.3). We believed that the desired cycloalkenes 15 and 16 could be synthesized from the diolefins 22 and 23 by applying ring-closing metathesis (RCM) chemistry. The carbon framework of 22 and 23 is identical to 4-methyl itaconic acid (21), which is commercially available.

![Figure 4.7. The new retrosynthetic route to target compounds 14 and 17.](image)

By creating the kinetic enolate of 21 (4-methylitaconate), we assumed that it would be simple to synthesize the racemic diolefin 22 by standard techniques (Scheme 4.1), but it turned out that the βγ-unsaturated 21 could not be alkylated. Adding a co-solvent such as hexamethylphosphoramide (HMPA) can increase the reactivity of alkyl cations. However, HMPA is highly carcinogenic, and a special permit is required to use this agent in Sweden. Consequently, we deemed DMPU to be an acceptable replacement for HMPA, and applying that co-solvent made it possible to alkylate 21 with 4-bromobutene, which furnished 22 in 30% yield. Apparently the enolate of 4-methyl itaconate is highly aggregated, thus this compound must be in a strongly polar environment to be reactive. Aggregation means that the positive metal ion binds to the negatively charged enolate, which is thereby rendered
Scheme 4.1. Synthesis of the proline isosteres."

unreactive. Addition of a strong polar aprotic solvent will cause the metal ions to chelate with the solvent, which, in turn, will free the enolate and make it more inclined to react with the electrophile. The addition of 0.4 equivalents of lithium iodide raised the yield of 22 to 48%.
The yields of this alkylation were low, because the stable isomerized product 2-methyl-but-2-enedioic acid 4-methyl ester was readily formed (10–40%). When we used 5-bromopentene as electrophile instead of 4-bromobutene, 23 was obtained in 42% yield. Although the yield in these novel alkylations was not impressive, we tested asymmetric alkylations with auxiliaries developed by Evans and Oppolzer, but, unfortunately all attempts failed. After the successful alkylations that had yielded the racemic compounds 22 and 23, it was time for metathesis reactions that were intended to give the corresponding cyclized racemic compounds 15 and 16. Initially, we tried to cyclize the successfully alkylated compounds and derivatives thereof using the first-generation Grubbs catalyst 24 and the Schrock's catalyst 25, these metathesis trials are summarized in Section 4.3.1 (Figure 4.11). When the second-generation Grubbs catalyst 26 became commercially available from Strem Chemicals in August 2000, we subjected the dienes 22 and 23 to high-yield cyclization with 3–8 mol percent tricyclohexylphosphine [1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydroimidazol-2-ylidene] [benzylidene]ruthenium (IV)) dichloride (26) in DCM at 40 °C,42 which yielded the RCM products 15 and 16 (98% and 85%, respectively).

The proline isosteres 15 and 16 were synthesized along a two-step reaction route with an overall yield of 47% and 35%, respectively. As previously mentioned, the old synthetic pathway to 15 involved five steps and an overall yield of 12%.

\*Reagents and conditions: (a) LDA, LiI, THF:DMPU (1:1), –80 °C 4-bromobutene; (b) LDA, LiI, THF:DMPU (1:1), 5-bromopentene, –80 °C; (c) 3–8 mol % second generation Grubbs’ catalyst (C_{46}H_{65}Cl_{2}N_{2}PRu), DCM, 40 °C.
4.3 The olefin metathesis reaction

The synthesis of the final products is described in section 4.4. This section (4.3) concerns metathesis and some metathesis trials that were conducted before the above-mentioned reaction conditions were discovered. Furthermore, a short history of the metathesis reaction is included here, along with a discussion of the catalysts and the mechanisms involved.

The metathesis reaction is actually very well known and has undoubtedly been performed by virtually every person with at least a background in junior high school chemistry, because ordinary acid/base neutralization is precisely such a reaction (Figure 4.8A). Metathesis is a double exchange reaction, which means that some molecules of the reactants exchange positions and create two new products. Olefin metathesis entails catalytically induced reactions in which olefins undergo bond reorganization and release volatile ethene, which constitutes the underlying driving force of the reaction (Figure 4.8B-C).\(^{29,30}\) The most reliable and most widely applied of these reactions are the ring closing metathesis (RCM) reaction, whereas the type of intermolecular metathesis referred to as cross metathesis (CM) is somewhat more complicated, because two reactants A and B can form the dimers AA, AB, and BB. The geometry of a CM product can be both cis and trans, even if the trans geometry is usually preferred. RCM reactions are run in very diluted solutions (~ 0.01 M) and the CM reactions in fairly concentrated solutions (~ 0.2 M). An ordinary flash column chromatography usually removes the catalyst but if it is absolutely necessary to remove all traces of catalyst it is possible to trap it with the use of lead tetraacetate or phosphine reagents such as P(CH\(_2\)OH)\(_3\) and PPh\(_3\)O).\(^{31}\)

In the 1950s, several patent applications described a new type of reaction, which at that time was called “coördination polymerization,” and the first articles describing such chemistry were published in the early 1960s.\(^{32,33}\) However, it was not until 1968 that the reaction was given its right name (olefin metathesis) and the underlying mechanism was correctly described in 1971 by Chauvin, Y.\(^{34,35,36}\) Olefin metathesis remained an obscure and

\[
\begin{align*}
\text{A} & \quad \text{HCl} + \text{NaOH} \rightarrow \text{H}_2\text{O} + \text{NaCl} \\
\text{B} & \quad \begin{array}{c}
\text{A} \\
\text{B}
\end{array} \rightarrow \\
& \quad \begin{array}{c}
\text{H}_2\text{C} = \text{CH}_2
\end{array} \\
\text{C} & \quad \begin{array}{c}
\text{R}_1 \\
\text{R}_2
\end{array} \rightarrow \\
& \quad \begin{array}{c}
\text{R}_1 \text{R}_2
\end{array} \rightarrow \begin{array}{c}
\text{H}_2\text{C} = \text{CH}_2
\end{array}
\end{align*}
\]

Figure 4.8. (A) The ordinary acid/base neutralization is a metathesis reaction; (B) the olefin ring closing metathesis reaction; (C) the olefin cross metathesis reaction.
unreliable reaction through the 1970s and 1980s due to the lack of commercially available well-defined catalysts. The catalyst revolution started in the early 1990s, research groups headed by R. R. Schrock and R. H. Grubbs published papers reporting that they had used molybdenum and ruthenium, respectively, to synthesize new and powerful, well-defined metathesis catalysts. The early molybdenum (Schrock) catalysts were highly reactive and sensitive to air, they decomposed in protic environments but they could yield metathesis products that were both trisubstituted and sterically hindered (Figure 4.9). The first generation of Grubbs catalysts were moderately reactive and slightly sensitive to air, but the commercially available 24 could tolerate almost any type of functionalities (e.g., esters, amides, ethers, alcohols, and carboxylic acids) and it could yield disubstituted and, in rare cases, also trisubstituted alkenes (Figure 4.9). Due to the higher reactivity, the commercially available Schrock catalyst was still a good option, but that changed in the late 1990s, when Grubbs developed, among other ones, the second-generation Grubbs catalyst 25, which surpassed the reactivity of the Schrock catalyst while retaining the air stability and excellent functional group compatibility of the first generation catalyst 24 (Figure 4.9). These catalysts could easily yield alkenes through metathesis that was trisubstituted and in some cases even tetrasubstituted. In 2000, Amir H. Hoveyda published a paper describing experiments that included the catalyst 26, which, after the first metathesis cycle, has the same reactive species as 25 (Figure 4.9). The second-generation Hoveyda/Grubbs catalyst 26 is, in most circumstances, equipotent to the second-generation Grubbs catalyst 25, although this can vary from better to worse. Despite the development of functional first-generation metathesis catalysts in the 1990s, it was not until the 2000s that the use of metathesis reactions made real headway and this approach became the tool of the average organic chemist. The second-generation Grubbs catalysts have had a major impact on the field of organic chemistry.

I wrote this during the summer 2005: “In my opinion it is very likely that the Nobel Prize in chemistry is imminent for Robert H. Grubbs and Richard R. Schrock, and possibly also Amir H. Hoveyda, for their work in developing metathesis catalysts.” Actually, my
prediction was almost true, as Robert H. Grubbs and Richard R. Schrock, and Chauvin, Y (for the correct mechanism) got the Nobel Prize 2005.

For readers who are unfamiliar with the metathesis reaction, it should be pointed out that the active catalysts of the first turnover are the original benzylidene species 24, 25, and 26, and the dissociation products are styrene derivatives. In the subsequent catalytic turnovers, the more reactive (and unstable) methylidene species E is the active catalyst, and the dissociation product is ethene (Figure 4.10). The RCM catalytic cycle with the Grubbs catalysts begins with the dissociation of tricyclohexylphosphine from 24 and 25, or, in the case of 26, with the loss of coordination of the isopropoxide moiety. The loss of the ligand generates the four-coordinate intermediate A. Species of A derived from catalysts 25 and 26 (N-heterocyclic carbene ligands) will have \( k_2 > > k_{-1} \), whereas species derived from 24 (triphenyl phosphine ligand) will have \( k_2 \sim k_{-1} \), which explains why the second generation of catalysts are more reactive then the first. In a formal \([2 + 2]\) addition, the benzylidene ligand in A attacks a diolefin, creating the metallacyclobutane B, which decomposes to release styrene and generate the key intermediate C. An intramolecular \([2 + 2]\) cycloaddition creates the metallacyclobutane D, which decomposes to yield the very active methylidene intermediate catalyst E and the cyclized compound F. The methylidene compound E attacks another diolefin, producing the metallacyclobutane G, decomposition of which liberates

Figure 4.10. General mechanism of the olefin ring-closing metathesis reaction.
ethene and again creates the key intermediate C. Ethene quickly evaporates, rendering $G \rightarrow C$ irreversible, which is the driving force of the metathesis reaction.

4.3.1 Metathesis trials

As mentioned in the previous section, several metathesis trials were performed on various cycloalkenes before the second-generation Grubbs catalyst was released (Figure 4.11). Since the attempts to use the first-generation Grubbs catalyst (24) for direct RCM of 22 had failed, we tried to cyclize the tert-butyl ester derivative with both 24 and the Schrock catalyst, but with no success. Inasmuch as it is known that electron-withdrawing groups reduce the reactivity in RCM, the next approach was to convert the carboxylic acid to the alcohol. Trace amounts (3%) of the cyclized alcohol product were obtained using the first-generation Grubbs catalyst. Encouraged by that result, we continued with the benzoylated derivative and obtained the cyclized product benzoic acid 5-methoxycarbonyl-cyclopent-1-enyl ester in 35% yield. This ester could be hydrolyzed and oxidized to yield the proline isostere 15, but that meant that this new metathesis strategy was hardly better than the old cyclopentadiene synthetic pathway (Figure 4.6). Luckily, the emergence of the second-generation Grubbs catalysts made it feasible to synthesize 15 and 16 directly from the corresponding diolefins. The second-generation Grubbs catalyst (25) also improved the yield of all other derivatives, except the tert-butyl ester derivative, which remained impossible to cyclize, probably due to steric hindrance. After successful synthesis of the scaffolds 15 and 16, we also tested synthesizing 4- and 7-membered cycloalkenes, as well as a tetrasubstituted cyclopentene (Figure 4.12). Attempts at synthesizing the tetrasubstituted alkene gave an isomerized anhydride (Figure 4.12). Trials aimed at making a 4-membered ring yielded the Cope rearranged product, and efforts focused on generating the 7-membered ring gave only degradation products. In all likelihood, the catalyst was trapped by the neighboring carboxylic acid functionality (or ester carbonyl). Another possibility is that intramolecular hydrogen bonding between the carboxylic acid and the ester puts the long alkene tail off distance to the dissubstituted alkene, thus lowering the population of the reactive conformer. This effect could also explain the lower yield of the cyclohexene 16 compared to the cyclopentene 15. The addition of titanium isopropoxide has been reported to increase the

![Figure 4.11. Metathesis trials aimed at synthesizing 5- and 6-membered cycloalkenes.](image-url)
yield in similar cases *i.e.* both unproductive chelates and problem with unreactive conformer. Unfortunately the addition of 10 mol % had no effect in this case.

**Figure 4.12.** Metathesis trials aimed at synthesizing a tetrasubstituted cyclopentene and 4- and 7-membered cycloalkenes.
4.4 Synthesis of the final products

The synthesized scaffolds 15 and 16 were subjected to two amide-coupling derivatization steps to yield the final products in series 14 and 17 (Scheme 4.2), which were subsequently used to optimize the activity of the lead compound 14[4]. The first derivatizations of scaffolds 15 and 16 were achieved by performing coupling reactions at r.t. with various amines taken from the P3 building blocks 27 (Figure 4.13), mainly using BOP-Cl (bis-(2-}

**Scheme 4.2.** Synthesis of the final products used for activity optimizations. 

*Reagents and conditions: (a) BOP-Cl, DIPEA, 27 (the P3-building blocks. HNR1R2), DMF; (b) LiOH, dioxane-H2O (1:1); (c) DCC:HOBt, Pab(Z), DIPEA, THF (50 °C); (d) TFMSA, anisole, DCM.

![Diagram of the synthesis process](image)

Figure 4.13. The P3 building blocks 27 (HNR1R2), **R = H in 14{7} and 31{7}, **R = tBu in 27{7}, 28{7}, and 30{7}.
Oxo-3-oxazolidinyl)phosphinic-chloride) as coupling reagent, which yielded 28 and 29. Surprisingly, trials with HATU (O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate), one of the most versatile coupling reagents known, resulted in sluggish reactions and low yields. Some of the sterically hindered anilines in 27 (the P3 building blocks) could be coupled only at elevated temperatures using BOP-Cl. Before the optimized coupling conditions were found we used 30\{7\} as a model compound and tested several other conditions (PyBOP, DCC:HOBt, EDC:HOBt, HATU in THF, or DMF at r.t. or under heating). The methylesters in the series 28 and 29 were hydrolyzed with lithium hydroxide in dioxane-water (1:1). This resulted in lithium carboxylates, which were dried by co-evaporation with methanol-toluene (1:1) and then coupled with Pab(Z) x 2 HCl using DCC:HOBt (dicyclohexyl carbodiimide:1-hydroxy benzotriazol) and DIPEA in THF (50 °C). Use of other coupling reagents (i.e. BOP-Cl, HATU, and PyBOP) in DMF did not improve the yields. The Z-protecting group and the tert-butyl-protecting group in members derivatized with 27\{7\} were simultaneously hydrolyzed using TFMSA in DCM at 0 °C, which yielded the target compounds in series 14 and 17. All chemical reactions gave better yields with the cyclopentene derivatives than with the cyclohexene derivatives.

Subsequently, we also synthesized the target compounds in series 31 and 32 (Scheme 4.3), that together with series 14, were used in a directional vector study (Table 4.1, Section 4.5). The scaffold 33 was easily prepared (90% yield) in a straightforward manner from commercially available 1-cyclopentene-1,2-dicarboxylic anhydride in methanol in the presence of zinc chloride. The target compounds in series 31 were synthesized in the same way as the members of series 14 and 17 (Scheme 4.3). The acid 15 was coupled with Pab(Z) x

**Scheme 4.3.** Synthesis of target compounds needed for the vector study.\(^a\)

\(^a\)Reagents and conditions: (a) methanol, ZnCl\(_2\); (b) BOP-Cl, DIPEA, 27 (the P3 building blocks HNR\(_1\)R\(_2\)), DMF; (c) LiOH, dioxane-H\(_2\)O (1:1); (d) DCC:HOBt, Pab(Z), DIPEA, THF (50 °C); (e) TFMSA, anisole, DCM.
2 HCl using DCC:HOBt and DIPEA, which generated the benzamidine(Z)-methylester 34 (90% yield; Scheme 4.3). Saponification with lithium hydroxide in dioxane-water gave the lithium salt 35 (85% yield), which was dried through co-evaporation with toluene/DCM (1:1) to afford water-free crystals. These crystals were dissolved in DMF (50 °C) and coupled with several P3 building blocks 27, using BOP-Cl as coupling reagent. The drying procedure after the saponification was necessary due to the polar and hygroscopic nature of the molecule. The Z-group was cleaved using TFMSA and anisole in DCM to yield the target compounds in series 32. All these compounds were racemic, but we purified 14\{I\} on a chiral column, and the enantiomers (S)- and (R)-14\{I\} could be separated and individually tested for activity.

The N-ethyl- and N-cyclohexyl-substituted anilines in the P3 building blocks 27 (Scheme 4.4) were synthesized from acetaldehyde or cyclohexanone and various anilines to form the corresponding imines, which were reduced using borane-pyridine and molecular sieves (4 Å) in methanol. Compound 27\{7\} was synthesized using o-toluidine, tert-butyl bromoacetate, and potassium carbonate in DMF at 80 °C.

In paper II, a total of 84 new molecules were synthesized and characterized by 1H-NMR, 13C-NMR, and high resolution mass spectroscopy.

**Scheme 4.4.** Synthesis of the commercially unavailable amines in the P3 building blocks 27.$^a$

$^a$**Reagents and conditions:** (a) acetaldehyde, molecular sieves (4 Å), borane-pyridine, methanol; (b) cyclohexanone, molecular sieves (4 Å), borane-pyridine, methanol; (c) tert-butyl bromoacetate, K$_2$CO$_3$, DMF (80 °C).
4.5 Structure-activity relationships

To fully elucidate the interactions between thrombin and the ligands in series 14, we co-crystallized α-thrombin with the racemate of 14{14} (Figure 4.14-4.16), which was the most potent compound at that time the X-ray analysis was performed. Figure 4.14 illustrates the overlay of the X-ray structure of the α-thrombin-14{14} complex and the α-thrombin-PPACK complex. Only the (R)-enantiomer of 14{4} has strong enough affinity for α-thrombin to be crystallized with it. The α-thrombin-(R)-14{14} and α-thrombin-PPACK complexes exhibit similar binding modes, as can be seen in Figure 4.14. A direct comparison with PPACK with respect to affinity for the protease may seem irrelevant, since PPACK, via its chloromethyl and ketone group, bind covalently to His57 and Ser195 (Figure 4.3). However, it has been reported that non-covalent inhibitors such as melagatran exhibit substantial affinity for thrombin and interact with the enzyme in the same way as PPACK.
does, and they form an extensive hydrogen bond network with Ser214 and Gly216.\textsuperscript{25} The benzamidine group of \((R)-14\{14\}\) fits nicely into the S1 pocket, and there are very strong electrostatic interactions between the amidine group and the carboxylate of Asp189, with N-O distances of 2.45 and 2.71 Å (Figure 4.15). Furthermore, in a manner similar to PPACK, the cyclopentene ring of \(14\{14\}\) fits well in the hydrophobic proximal pocket (S2) of thrombin. In the X-ray structure of the \(14\{14\}\)-thrombin complex, the electron density of the P3 5-chloro-2-methylphenyl is slightly disrupted in relation to the D pocket, which indicates that the phenyl moiety adopts more than one conformation (Figure 4.16 and 4.17). As can be clearly seen in Figures 4.14 and 4.17, the inhibitor does not occupy the whole D pocket, and, in light of that observation, we synthesized inhibitors \(14\{19–22\}\).

![Lead compound](image)

**Figure 4.18.** The activity of some compounds showing the synergic effects of 2,5-phenyl substitution in the \(14\) series and the lower affinity of the six-membered derivative \(17\{4\}\) compared to the five-membered analog \(14\{4\}\).

Further optimizations of cyclopent-2-ene-1, 2-dicarboxylic acid derivatives based on X-ray analysis data led to compounds that exhibit 20 times greater activity against thrombin *in vitro* compared to the lead compound \((R)-14\{4\}\) (Figure 4.18).\textsuperscript{27} The 2,5-substitutions on the phenyl moiety in the P3 position constitute the major improvement. Due to the disrupted electron density in the D pocket, either one of the two substituents probably interacts with the D pocket (Figure 4.16). An alternative explanation for the increased activity is that adoption of the conformation shown in Figure 4.17 would lower the energy of ligand bonding conformation. The synergic effect of 2,5-substitution is illustrated by comparing the 2,5-methoxy-substituted compound \(14\{20\}\) (79 nM) with the *ortho*-substituted \(14\{1\}\) (240 nM) and *meta*-substituted \(14\{6\}\) (250 nM) (Figure 4.18). Moreover, larger groups on the nitrogen...
in the P2-P3 amide linker further improved the activity (14{22}, 49 nM), because they allowed the P3 phenyl moiety to adopt the thermodynamically favorable cis configuration around the rotamerically hindered P2-P3 amide linker. Moreover, the increased flexibility of the cyclohexene ring in series 17, did unfortunately not, improve the ligand-enzyme interactions compared to the cyclopentene-containing analogs in series 14, indicated by the comparison of 17{4} and 14{4} (Figure 4.18).

Continuing this work, we performed a directional vector study of the isomeric compounds 14{1–4}, 31{1–4}, and 32{1–4} (Table 4.1). The spatial dissimilarity of target compounds in series 14, 31, and 32 is due to different bond hybridization of the P1- and P3-directing atoms of the central ring scaffold. We assumed that the best activity would be achieved by using the same hybridization configuration as in the D-Phe-Pro-Arg motif and PPACK. Target compounds in series 14 and Pro have sp^3 hybridization of the P1-directing atom (tetrahedral \rightarrow \text{theoretical bond angle 109.5°}) and sp^2 hybridization of the P3-directing atom (planar \rightarrow \text{theoretical bond angle 120°}). The bond hybridization of the directing atoms is reversed in target compounds in series 32, whereas target compounds in series 31 have only sp^2-directing atoms. The theoretical dihedral angle between the P1- and P3-carbonyl atoms in the P2 scaffold is 0° in series 31 but is < 0° in Pro and in the series 14 and > 0° in the series 32. Examination of the potency of the target compounds 14{1–4} and 32{1–4} given in Table 4.1 indicates that reversing the hybridization of the directing atoms compared to the D-Phe-Pro-Arg motif lowered the activity towards thrombin. On average, members of series 32 show a 20-fold decrease in activity compared to target compounds in series 14 that have the same P3 moiety. This also applies to the target compounds 31{1–4}, in which the shift from sp^3 to sp^2 resulted in, on average, a 50-fold decrease in activity compared to the analogs of target compounds in series 14. Thus, we may safely conclude that within the series of P2-cyclopentene dicarboxylic derivatives, the motif with P1-sp^3 and P3-sp^2 directional vectors

<table>
<thead>
<tr>
<th>Cpd</th>
<th>IC_{50} (µM)</th>
<th>Cpd</th>
<th>IC_{50} (µM)</th>
<th>Cpd</th>
<th>IC_{50} (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14{1}</td>
<td>0.24</td>
<td>31{1}</td>
<td>24</td>
<td>32{1}</td>
<td>7.8</td>
</tr>
<tr>
<td>14{2}</td>
<td>4.6</td>
<td>31{2}</td>
<td>&gt; 130</td>
<td>32{2}</td>
<td>22</td>
</tr>
<tr>
<td>14{3}</td>
<td>0.68</td>
<td>31{3}</td>
<td>33</td>
<td>32{3}</td>
<td>19</td>
</tr>
<tr>
<td>14{4}</td>
<td>0.97^a</td>
<td>31{4}</td>
<td>28</td>
<td>32{4}</td>
<td>16</td>
</tr>
</tbody>
</table>

^a The lead compound, the (R)-enantiomer.
provides the best interactions with thrombin, which is consistent with the directional vectors in the D-Phe-Pro-Arg motif.

4.6 Conclusions

By using RCM chemistry, we were able to develop a new and improved synthetic pathway to the previously reported thrombin inhibitors in series 14, which are based on the D-Phe-Pro-Arg motif. A total of 84 compounds were synthesized in the series 14, 17, 31, and 32. All these compounds were characterized, including the 34 final products, which were also tested against thrombin for inhibitory properties. Initial optimizations of the lead compound 14 (970 nM) yielded thrombin inhibitors with activity in the nanomolar range. X-ray crystallographic and computer analyses of 14 (220 nM) led to synthesis of compound 1 (49 nM). A directional vector study illustrated the importance of using P1- and P3-directional vectors that are consistent with the D-Phe-Pro-Arg motif. The results of the SAR analysis indicate that the compounds in series 14 can be further optimized to provide more potent inhibitors.
5 Inhibitors of the HCV NS3 protease (Paper III)

Based on the therapeutic success of targeting the HIV protease, the HCV NS3 protease represents a major target in the search for antiviral agents against the hepatitis C virus (HCV).\(^48\) Recently, a phase II study demonstrated the antiviral efficacy of a NS3 protease inhibitor in patients suffering from hepatitis C.\(^85\)

HCV is a single-stranded positive RNA virus of the family Flaviviridae, and it has a narrow host range in that only humans and chimpanzees are susceptible to infection.\(^49\) Chronic infection with HCV is a major health problem that can cause cirrhosis, hepatocellular carcinoma, and liver failure.\(^50\) The World Health Organization (WHO) has estimated that approximately 170 million people are infected with HCV worldwide (Table 5.1).\(^51\) The virus is spread through blood contact and through exchange of bodily fluids (e.g., via blood transfusions, recycling of infected needles, and sexual intercourse). Around 20% of those who have been infected for 10 to 20 years develop cirrhosis, and about 5% of such prolonged cases progress to liver cancer.\(^52\) HCV is one of the major indications for liver transplantation, and at present there is no vaccine.\(^53\) The only therapy available is expensive, and comprises of a high dose of PEGylated α-interferons in combination with ribavirin, and it results in only an approximately 50% sustained virological response in infected patients patients of genotype 1, the dominant genotype in the western world.\(^54\) The limited efficacy of this treatment clearly highlights the immense need for new and more efficacious therapeutic options.

The life cycle of HCV is illustrated in Figure 5.1, and the letters in boldface type in this discussion refer to the stages shown in the figure. The cycle begins when the virus enters the blood and comes in contact with a liver cell (hepatocyte) (A).\(^54\) The glycoproteins E1 and E2 bind to the receptors CD81 and LDLR on the hepatocyte, and the virus particle is delivered to the cytoplasm of the cell through endocytosis (B). In the cytoplasm, the virus is uncoated (C), and the RNA is released and translated to a polyprotein by the host cell ribosomes (D). The HCV polyprotein is cleaved into at least 10 active viral proteins by host enzymes and the viral

<table>
<thead>
<tr>
<th>WHO region</th>
<th>Total pop. ( Millions)</th>
<th>Infected pop. ( Millions)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Africa</td>
<td>602</td>
<td>31.9</td>
</tr>
<tr>
<td>Americas</td>
<td>785</td>
<td>13.1</td>
</tr>
<tr>
<td>Eastern Mediterranean</td>
<td>466</td>
<td>21.3</td>
</tr>
<tr>
<td>Europe</td>
<td>858</td>
<td>8.9</td>
</tr>
<tr>
<td>Southeast Asia</td>
<td>1500</td>
<td>32.3</td>
</tr>
<tr>
<td>Western Pacific</td>
<td>1600</td>
<td>62.2</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>5811</strong></td>
<td><strong>169.7</strong></td>
</tr>
</tbody>
</table>

Table 5.1. Number of people infected with the hepatitis C virus in regions designated by the WHO.
enzymes NS2 and NS3 (E). The viral capsule, which is assembled in the ER of the hepatocyte (F), consists of at least three viral proteins: the core of the nucleocapsid (C) and two glycoproteins (E1 and E2). The polymerase NS5B is responsible for replication of the RNA genome to a double RNA helix (G). The double-stranded RNA is unwound by the NS3 helicase (H), and the positive single-stranded part is packaged into the assembled nucleocapsid (I) to form a mature virion. The constructed virions are subsequently released from the cell through vesicle fusion and are ready to infect other hepatocytes (J).

As enlightenment to fully understand the completeness of the virus cycle, I would like to point out that only some single-stranded RNA are packaged into a nucleocapsid and the

**Figure 5.1.** The life cycle of HCV. The cycle comprises the following stages: (A) attachment; (B) endocytosis; (C) uncoating of the virus; (D) translation of RNA to the polyprotein; (E) proteolytic processing of the polyprotein; (F) formation of the nucleocapsid; (G) replication; (H) unwinding of the double-stranded RNA; (I) viral assembly and vesicle transport; (J) vesicle fusion and virion release.
other ones are used as templates in the translation process to produce more polyproteins (D). Moreover, the negative single stranded RNA, that together with the positive single-stranded RNA forms the RNA-double helix, can after unwinding (H) be used as template in the replication to produce more positive single-stranded RNA (G).

The HCV genome and its encoded gene products have recently been characterized in detail.55 The genome consists of a 5’ non-translated region (NTR), which includes the internal ribosome entry site (IRES), followed by the open reading frame (ORF) that is translated to a single polyprotein (Figure 5.2). There is also another NTR in the 3’ region. The HCV polyprotein is made up of approximately 3000 amino acids, which are proteolytically processed into four structural proteins (C, E1, E2, and P7) and six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) (Figure 5.3).56 These cleavages are mediated by host enzymes and the viral proteases NS2 and NS3. The host enzymes cleave the structural proteins, and the NS2 enzyme is responsible for cleavage of the NS2-NS3 junction through autocatalysis, which frees the N-terminal part of the NS3 protein. The NS3 protein is a bifunctional enzyme: its N-terminal domain exhibits protease activity, and its C-terminal domain displays RNA helicase/ATPase activity. The NS3 protease is responsible for the autocatalytic cis cleavage of the NS3-NS4A junction and the trans cleavage of the NS4A-NS4B junction. The NS3-NS4A complex mediates the cleavage at the NS4B-NS5A and NS5A-NS5B junctions.

![Figure 5.2. The single-stranded positive RNA genome of the hepatitis C virus.](image)

![Figure 5.3. The polyprotein that is expressed by the ORF of the HCV genome.](image)
5.1 Development of NS5A/5B substrate-based inhibitors of the HCV NS3 protease

In the late 1990s, it was discovered that the HCV NS3-NS4A protease complex is feedback inhibited by several of its cleavage products.\textsuperscript{57,85a} Compound 36 corresponds to the N-terminal cleavage product of a substrate derived from the NS5A/NS5B cleavage site, and it inhibits the NS3 protease with an IC\textsubscript{50} of 7100 nM (Figure 5.4).\textsuperscript{85a} The iterative structure based design process started with the substrate-based hexapeptide 36, which was N-terminally capped with an acetyl group, and the oxidatively sensitive cysteine was replaced with norvaline. This gave less polar inhibitors that had greater stability, but the activity remained low. Real progress was made in when a benzyl substituted hydroxyproline moiety was introduced instead of the proline moiety, this gave the modestly potent hexapeptide 37.\textsuperscript{85b} Hexapeptides are not viable as drugs, because they have a large molecular mass, and they are usually too polar to pass through cell membranes, so efforts were made to achieve truncation of the P5 and P6 groups. Unfortunately, this resulted in loss of inhibitory activity, but replacing the benzyl ether by a naphthyl ether and performing a ring fusion of the propyl moiety of norvaline to a cyclopropyl group, as well as another ring fusion of isoleucine to cyclohexyl glycine, resulted in the tetrapeptide inhibitor 38.\textsuperscript{85c} Although the tetrapeptide inhibitors at this stage were still less potent then their hexapeptide counterparts, they were smaller and less polar due to the

![Figure 5.4](image-url)
removal of the two Asp amino acids, thus they were much more appropriate as lead candidates according to the Lipinski rule of five. Extensive optimization of the P2 substituent led to compound 39, which had a respectable IC$_{50}$ value of 800 nM against the HCV NS3 protease. Optimizations of the P1 group led to the vinylcyclopropyl derivative 40, which further improved the potency to a promising IC$_{50}$ of 170 nM (Figure 5.5). Making the P3 building block a little more bulky and extension of the P2 substituent with a phenyl moiety gave compound 41 an impressive IC$_{50}$ of 1 nM. However, 41 and similar compounds with excellent IC$_{50}$ values had poor membrane permeability and were thus not suitable as drugs. It was obvious that some major structural changes had to be made. Earlier NMR analysis of compound 37 had shown that the P1 and P3 groups in the active conformation are located close to each other and undergo extensive rigidification upon binding. A macrocyclization between P1 and P3 would give rise to less peptidic structure, and the rigidification would probably lead to a more desirable pharmacokinetic profile than the corresponding linear peptides. Truncation of the P4 moiety, capping the P3 amine with a cyclopentyl carbamate, and using cyclopentyl glycine in the P3 position yielded compound 42, which had an IC$_{50}$ of 400 nM. This was a promising result, because the activity was still moderately high despite

![Figure 5.5](image-url)
the truncation of the P4 moiety and introduction of the new P3-cyclopentyl glycine moiety. Further optimizations of the P2 substituent and a macrocyclization between the P1 and the P3 position of 42 led to the excellent inhibitor 43 (BILN 2061), which has very good membrane permeability and an EC<sub>50</sub> of 3 nM against replicon cells<sup>85h</sup>. The clinical phase II study of BILN 2061 showed that it is an effective protease inhibitor with an antiviral impact in humans infected with HCV. Treatment with BILN 2061 (200 mg) twice a day for two days decreased the viral load in patients infected with HCV genotype 1 to nearly undetectable levels within 24–28 h.<sup>85h</sup> However, the antiviral efficacy of BILN 2061 is less pronounced in patients with HCV genotype 2 or 3.<sup>58</sup> Further clinical trials are currently on hold due to cardiotoxicity observed in recent toxicological studies in monkey receiving high doses of BILN 2061 for four weeks.

Previous investigations of thrombin inhibitors performed in our laboratory have shown that proline can be successfully replaced with five- and six-membered carbocyclic isosteres (Figure 5.6).<sup>59,60</sup> We were interested to explore whether the structural motif of the cyclopentene moiety, i.e. a trans-4-hydroxy-cyclopentene dicarbonyl derivative, could provide advantages over the P2-hydroxyproline moiety found in compound 36-43. To generate the initial SAR from this novel series we selected 7-methoxy-2-phenylquinolin-4-ol as P2 substituent and a variety of P1 and P3 amino acid derivatives (Figure 5.7). Although BILN 2061 has entered clinical studies, we believed that the less complicated compound 41 would be a better structural motif to mimick

![Figure 5.6](image1)

![Figure 5.7](image2)

![Figure 5.7](image3)
Among other compounds, we synthesized 44a{3,4}, which is the hydroxy-cyclopentene analog of the L-hydroxyproline compound 41 (Figure 5.7). An activity comparison of the two compounds shows that they are equipotent, which proves that in this case the hydroxy-cyclopentenes are good L-hydroxy proline bioisosteres.

5.2 Synthesis of the scaffold

A retrosynthetic analysis of the compounds in series 44a confirmed that they could be synthesized from the chiral scaffold A by two ordinary peptide couplings and one Mitsunobu reaction (Figure 5.8).61,86 We reasoned that it should be possible to synthesize the scaffold A from the diester B by a regioselective monohydrolysis. Synthesis of the alcohol B should be feasible through stereoselective reduction of the ketone C. Also, the αβ-unsaturated ketone C should be available through olefination of D. The enantiomeric synthesis of D is described in the literature.62 Regrettably, the olefination of D led to racemization, so we instead chose to use the more easily synthesized racemic syn derivative of D, namely compound 48 (Scheme 5.1).

![Figure 5.8. Retrosynthetic route to target compounds 44a.](image)

**Scheme 5.1.** Synthesis of the previously reported intermediates.\(^a\)

![Scheme 5.1](image)

\(^a\)Reagents and conditions: (a) \(p\)-toluene sulfonic acid, methanol, reflux; (b) \(\text{KMnO}_4\) (aq), 0 °C; (c) acetic anhydride, 130 °C; (d) \(\text{CaCO}_3\), DMF, 100 °C.
The ketone 48 was synthesized as previously reported from commercially available and inexpensive (syn)-tetrahydrophtalic anhydride 45 (Scheme 5.1). The anhydride 45 was esterfied and oxidatively cleaved to the dicarboxylic acid 46, which was cyclized and decarboxylated to the syn-cyclopentanone 47. The ketone was α-brominated with cupric bromide and β-eliminated to the olefin 48 using calcium carbonate. As mentioned in the discussion concerning the retrosynthesis, we tried to produce chiral C from chiral D by using CuBr2/CaCO3 or PhSeBr/LDA followed by oxidation, but this strategy always resulted in the racemate 48. The racemization of 48 was confirmed by polarimetry and NMR analysis performed using the chiral shift reagent europium-tris[3-(heptafluoropropyl-hydroxymethylene)(+)-camphorate].

The ketone 48 was reduced to the alcohol 49 in a 6:1 diastereomeric ratio (92%) using sodiumborohydride in cold (–30 °C) methanol to reduce the possibility of unwanted 1,4-addition (Scheme 5.2). When the reduction was tried at room temperature, the yield was poor and the syn/anti ratio was 1:1. It has been reported that adding CeCl3 will decrease the amount of 1,4-addition, but in our study that approach did not improve the yield or the diastereoselectivity, and instead it actually diminished both. We assumed that syn-49 was the major compound and that anti-49 was the minor compound, since the βγ-unsaturated ester probably acted as a steric hindrance and guided the hydride donation to the opposite face. This hypothesis was confirmed by experiments using nuclear Overhauser effect spectroscopy (NOESY; Section 5.2.1). The next step was the monohydrolysis of 49 to 50. We believed that it would be possible to achieve selective monohydrolysis of the βγ-unsaturated ester, leaving the αβ-unsaturated ester intact. This should be feasible for two reasons. First, hydrogen bonding between the 4-hydroxyl and the carbonyl oxygen of the βγ-unsaturated ester is plausible, and this neighboring group participation (NGP) effect makes the βγ-unsaturated carbonylcarbon more electropositive and thus more inclined to be hydrolyzed. Second, the carbonyl carbon in an αβ-unsaturated ester has greater electron density than a carbonyl carbon of a βγ-unsaturated ester, hence it is less electropositive. The syn/anti (6:1)
diastereomeric mixture 49 was monohydrolyzed using 1.0 equivalent of LiOH in dioxane/water, and the hydrolysis mixture could be further purified by crystallization (hexane/diethylether) to pure monomethylester 50. The yield was not impressive (27%), but it was taken after several crystallizations without regeneration of any material. The regiochemistry of 50 was determined by a heteronuclear multiple bond correlation (HMBC) spectrum see section 5.2.1 for further information.

5.2.1 Structure determination of the scaffold using 2D-NMR

In a NOESY spectrum, hydrogens that are in proximity to each other exhibit nuclear Overhauser effects (NOEs), thus it is possible to distinguish syn-49 from anti-49 (Figure 5.9). The reduction of 48 described in the previous section yielded a syn/anti (6:1) diastereomeric mixture of 49, which was purified by flash column chromatography. Unfortunately, the diastereomer of 49 that was formed in a smaller amount (presumably anti-49) was always strongly contaminated with the predominant diastereomer (presumably syn-49). The presumed anti-49 was synthesized from the presumed syn-49 by use of the Mitsunobu inversion reaction (Scheme 5.3). In the NOESY spectrum of the presumed syn-49, $H_1$ and $H_4$ interacted with the same methylene hydrogen ($H_{3\beta}$), which confirmed that the compound did

**Scheme 5.3.** Inversion of the stereochemistry using the Mitsunobu reaction.$^a$

$^a$Reagents and conditions: (a) BnCOOH, PPh$_3$, DIAD, dry THF; (b) NaOMe, MeOH.

*mixture of 49, which was purified by flash column chromatography. Unfortunately, the diastereomer of 49 that was formed in a smaller amount (presumably anti-49) was always strongly contaminated with the predominant diastereomer (presumably syn-49). The presumed anti-49 was synthesized from the presumed syn-49 by use of the Mitsunobu inversion reaction (Scheme 5.3). In the NOESY spectrum of the presumed syn-49, $H_1$ and $H_4$ interacted with the same methylene hydrogen ($H_{3\beta}$), which confirmed that the compound did

**Figure 5.9.** Significant NOE effects in syn-49 (illustrated by the 1S,4R enantiomer) and anti-49 (illustrated by the 1S,4S enantiomer), and the structure-determining HMBC couplings in 50.
indeed have the \textit{syn} configuration (Figure 5.9). Also, in the NOESY spectrum of the presumed \textit{anti-49}, \(H_4\) interacted with \(H_{5\alpha}\) and \(H_1\) interacted with \(H_{5\beta}\), which corroborated the \textit{anti} configuration (Figure 5.9).

To confirm the regiochemistry of \(50\), we performed an HMBC experiment, because the spectra that are produced can reveal \(^{13}\text{C}\leftrightarrow\text{H}\) couplings that are separated by two or three bonds, even those that span heteroatoms. The HMBC spectrum we obtained showed the expected interactions between the methylester hydrogens and the carbonyl carbon that also participated in interactions with the alkene hydrogen (Figure 5.9). These interactions confirmed that the synthesized compound \(50\) was the \(\beta\gamma\)-unsaturated acid. The \textit{syn} stereochemistry of \(50\) was verified by a NOESY spectrum that showed the same relevant NOEs as seen for \textit{syn-49}.68
5.3 Synthesis of the final products

The carboxylic acid 50 was coupled with the P1 building blocks in series 51 (H₂NCHR¹COOtBu) to yield the amides 52 (Scheme 5.4, and Figure 5.10). The secondary alcohols 52 were coupled with 7-methoxy-2-phenylquinolin-4-ol (R²OH) using the Mitsunobu reaction, which gave the ethers 53. The methylesters 53 were hydrolyzed to the carboxylic acids 54 and then coupled with the P3/P4 building blocks 55 (H₂NR³) to provide the amides 56 (Figure 5.10). These amides were purified by HPLC, but, of all twelve

Scheme 5.4. Synthesis of the target compounds. a

Reagents and conditions: (a) DIPEA, HATU, 51 (P1 building blocks), 0 ºC, DMF; (b) R²OH, (methoxy-2-phenyl-quinolin-4-ol), PPh₃, DIAD, THF; (c) LiOH, dioxane/water (1:1); (d) 55 (P3/P4 building blocks), DIPEA, coupling reagent (HATU and DMF or DCC/HOBt and THF); (e) triethylsilane, TFA, DCM.

Figure 5.10. The P3/P4 building blocks in series 55 (HNR²R³) (left) and the P1 building blocks in series 51 (H₂NCHR¹COOtBu) (right).
of these diastereomeric pairs, only one pair could be separated into two compounds, namely 56a\{2,2\} and 56b\{2,2\}. The tert-butyl esters in 56 were hydrolyzed to target compounds 44, using TFA and triethylsilane as a cation scavenger.70 After HPLC chromatography, another four of the target compounds in series 44 could be separated into the chiral final products 44a and 44b. The chiral compounds (44a and 44b), the diastereomeric mixtures (44), and two tert-butyl esters (56) were tested for NS3-protease-inhibiting properties. The activity data and complete structures of the tested compounds are presented in Section 5.5. (Table 5.2). The stereochemistry of the diastereomers was confirmed by ROESY and TOCSY 2D-NMR spectra in combination with computer calculations (Section 5.4).

The P1 and P3/P4 building blocks in series 51 and 55 were all synthesized from commercially available amino acids, with the exception of the amines 51\{1\} and 55\{6\}, which could be purchased. The P1 building block 51\{2\} was easy to produce from (S)-2-benzyloxy carbonyl-amino-pentanoic acid (57) by tert-butyler protection using Boc\_2O followed by Z-deprotection using catalytic hydrogenation (Scheme 5.5). The cyclopropane derivative 51\{3\} was synthesized from (1R,2S)-1-amino-2-vinyl-cyclopropanecarboxylic acid ethyl ester (58).69,71,72,73 The ethylester was hydrolyzed and the amine was Fmoc protected (59).74 The carboxylic acid was tert-butyl ester protected using TBTA, and the Fmoc was removed using piperidine in DMF.75 The target compound 51\{3\} could be purified by flash column chromatography, but it was not preferred as the free amine 51\{3\} decomposed on the column; instead, coupling of the crude 51\{3\} to the scaffold 50 as quickly as possible was favored. The free amine 61 was synthesized from 60 (Boc-(R)-cyclohexylglycine) through methylester protection using silver(II)oxide and methyl iodide, and the Boc group was deprotected using TFA (Scheme 5.6). The amine 61 was coupled with Z-(R)-Val-OH, and the
Z-group was deprotected using catalytic hydrogenation, which yielded the P3 building block 55{1}. The P3 building block 55{2} was synthesized by the same protocol but using the (S)-amino acids instead of the (R)-amino acids (Scheme 5.6). Synthesis of 55{3} was begun by using Boc2O and TEA in dioxane/water (1:1) to achieve Boc protection of tert-leucine (64) (Scheme 5.7). The acid was coupled with 63 ((S)-amino-cyclohexyl-acetic acid methyl ester), an intermediate formed during synthesis of 55{2}, which yielded the amide 65. The Boc group was removed using TFA and TES in DCM, and that gave the P3/P4 building block 55{3}. The methylamide derivative 55{4} was synthesized from 65, an intermediate in the

**Scheme 5.6.** Synthesis of the P3/P4 building blocks 55{1} and 55{2}. a

**Reagents and conditions:** (a) Ag₂O, methyl iodide, acetone; (b) TFA, triethyl silane, DCM; (c) Z-(R)-Val-OH, HATU, DIPEA, DMF; (d) Pd-C, 95% ethanol, H₂; (e) Z-(S)-Val-OH, HATU, DIPEA, DMF.

**Scheme 5.7.** Synthesis of the P3/P4 building blocks 55{3} and 55{4}. a

**Reagents and conditions:** (a) Boc₂O, TEA, dioxane/water (1:1); (b) 63, HATU, DIPEA, DMF; (c) TFA, TES, DCM; (d) LiOH, dioxane/water (1:1); (e) methylamine, DIPEA, HATU, DMF.
synthesis of $55\{3\}$. Thereafter, the methylester $65$ was hydrolyzed, the acid was coupled with methylamine, and, lastly, the Boc group was removed using TFA (Scheme 5.7). The $N$-methylated species $55\{5\}$ was synthesized from the commercially available $66$ (Fmoc-(S)-cyclohexylglycine-OH) (Scheme 5.8). First the amide nitrogen in $66$ condensed with paraformaldehyde to give an imine, which was attacked intramolecularly by the carboxylic acid to form an oxazolidinone intermediate. The oxazolidinone was hydrolyzed with TFA to yield the $N$-methylated compound, which was coupled with methylamine to give the amide $67$. The Fmoc-group was removed with piperidine in DMF, and the resulting amine was coupled with Boc-tert-leucine, and finally the Boc group was removed using TFA to yield the P3/P4 building block $55\{5\}$.

The P2-substituent 7-methoxy-2-phenyl-quinolin-4-ol ($R^2$OH) was synthesized as described in the literature from ethyl benzoylacetaete and $m$-anisidine through imine formation and a high temperature condensation reaction (ethanol as leaving group) (Scheme 5.9).

To summarize the syntheses, it can be said that a total of 63 novel compounds were produced, and they were characterized by NMR. Also, 18 final products were synthesized and tested for activity against the HCV NS3 protease (Section 5.5).

*Reagents and conditions: (a) paraformaldehyde, p-TsOH, toluene; (b) TFA, triethyl silane, DCM; (c) HATU, DIPEA, methylamine, DMF; (d) piperidine, DMF; (e) Boc-tert-leucine, DIPEA, HATU, DMF; (f) TFA, triethylsilane, DCM.

Scheme 5.9. Synthesis of the P2-substituent ($R^2$OH).

*Reagents and conditions: (a) 4 M HCl, reflux in toluene; (b) diphenyl ether, 280 °C.
5.3.1 Chemical stability

A successful route to the final products in series 44a was described in the previous section. However, as will be shown here, these compounds can be unstable, so it was necessary to implement careful control of reaction conditions in the synthetic route. It is a known fact that 1,2-unsaturated esters are susceptible to 1,4-nucleophilic attack, which initially presented a problem in the synthesis of the ethers in series 53. When we used excesses (> 2 equiv.) of triphenylphosphin and DIAD, we obtained not only the desired ether, but also the 1,4-DIAD adduct and this byproduct was confirmed by NMR and Maldi-TOF analyses (for spectra see supporting info to paper III) (Figure 5.11). To circumvent this undesired reactivity in the continued synthesis of ethers 53 less excess of reagents was generally employed. At this point, it is also important to realize the base liability of the target compounds in series 44. Our earlier synthetic pathways had used the ethylester variant of the P1 building block 58, but we found that, during hydrolysis, the P2 substituent underwent β-elimination more readily than the ethylester was hydrolyzed. (Figure 5.12). NMR and LC/MS data are provided as supplementary information in paper III. We tried several different bases and conditions to help diminish or eliminate the β-elimination problem, but all failed. These attempts included the hydrolysis reagents LiOH (1–8 equiv.), KOH (1–8 equiv.), HCl (6 and 12 M), pig liver
esterase and LiOH (1 equiv.), KOSiMe₃, TFMSA, and BBr₃. Microwave assisted organic chemistry LiOH (1–8 equiv.) or HCl (6 M). Transesterification reagents tert-butylacetate and potassium tert-butoxide (0.05–3 equiv.).

In summary, these compounds show some susceptibility of 1,4 Michael’s addition reactivity and the potential of quinoline β-elimination.

5.4 Structure determination of the target compounds using 2D-NMR

Due to the lack of success in synthesizing a chiral scaffold, it was necessary to perform preparative LC/MS to be able to isolate some members of series 44 as chiral compounds. Based on activity measurements, we assumed that the most active diastereomer would have the same stereochemistry as the lead compound 41, in other words that it would have 1R,4R stereochemistry in the cyclopentene ring. To confirm the stereochemistry we subjected 44a{2,3} and 44b{2,3} to TOCSY and NOE (ROESY and NOESY) analysis. In a TOCSY spectrum, it is possible to see the couplings of entire spin systems (Figure 5.13, left). That is to say, because all the PnαH (P1αH, P2αH, P3αH, and P4αH) are part of different spin-correlation systems, a TOCSY spectrum will reveal the chemical shift of both the PnαH and the corresponding PnNH. This information is needed to interpret NOE spectra, which disclose spatial relationships between hydrogens and therefore make it possible to determine which hydrogens are in proximity to each other. According to computer models, there should be a relevant difference in the distance between the P3NH and P2αH of the diastereomers, making it possible to distinguish between them (Figure 5.13, right). In Figures 5.14 and 5.15 (showing TOCSY spectra of 44a{2,3} and of 44b{2,3}), there are a total of four correlation lines, which respectively correspond to the P1, P2, P3, and P4 spin systems.
**Figure 5.14.** The designations of 44a \{2,3\} (top) and its TOCSY spectrum (below).

**Figure 5.15.** The designations of 44b \{2,3\} (top) and its TOCSY spectrum (below).
The first line (lowest chemical shift) of \(44a_{2,3}\) is the P4αH line, followed by the P2αH, P1αH, and P3αH lines. There is a slightly different order for \(44b_{2,3}\), namely first P4αH, then P1αH and P2αH, and last the P3αH line. The ROESY and NOESY spectra were identical with regard to the NOE interactions; we chose the ROESY spectra for further studies, and the important parts of the spectra can be seen in Figure 5.16. Figure 5.17 presents plausible configurations (energy minimized) of the diastereomers, which are used to explain the measured NOE interactions.\(^{78,79}\) The closer the distance between the molecules, the stronger the NOE interaction, and a useful guide is as follows: strong cross peaks, 2.0–2.5 Å; medium cross peaks, 2.0–3.0 Å; weak cross peaks, 2.0–5.0 Å.\(^{80}\) The P3NH and P4NH show the expected NOE interactions between their corresponding α-hydrogens. The NOE effects between P1NH and P1αH (16↔17) is hard to see due to proximity to the stronger P1NH↔P2αH (16↔15) NOE interaction. It is also a possibility that such interaction between P1NH and P1αH (16↔17) is really weak (2.95 Å in model) and actually undetectable. Moreover, the NOE interactions between P4NH and P3αH (8↔9) and between P1NH and P2αH (16↔15) are clearly visible. As illustrated in Figure 5.16, the intensity patterns of these two diastereomers are similar, with the exception of the NOE interaction for P1NH and P2αH (11↔15). Based on these results, it can be concluded that the structure-determining interaction between P1NH and P2αH (11↔15) is stronger in \(44b_{2,3}\) than in \(44a_{2,3}\).

The weaker NOE interaction of 11↔15 in \(44a_{2,3}\) compared to \(44b_{2,3}\) indicates that \(44a_{2,3}\) has the 1R,4R stereochemistry in the cyclopentene ring.
Figure 5.16. The designations of 44a{2,3} (top left) and 44b{2,3} (top right), and the ROESY spectra showing the interactions between the Pn-NH with Pn-αH hydrogens in 44a{2,3} (lower left) and 44b{2,3} (lower right).

Figure 5.17. Models of 44a{2,3} (left) and 44b{2,3} (right) showing the theoretical distances (Å) between Pn-NH→Pn-αH.
5.5 Structure-activity relationships of the final products

The final products in series 44 are very active in enzyme assays, so the SAR data on these compounds can be used as a tool in future projects focused on scaffold hopping (mimicking). All inhibitors discussed below contain the 7-methoxy-2-phenyl-quinolin-4-ol group as P2 substituent, because this group has had ample precedence in previous work, and it apparently stabilizes the catalytic machinery in the correct geometry by shielding the catalytic triad of the protease from exposure to the solvent. In addition, this P2 substituent probably interacts with the helicase domain of the NS3 protein, which enhances the overall activity.

The final products in series 44a are more potent then the corresponding diastereomers in series 44b (Table 5.2). The P2 hydroxycyclopentene moiety in series 44a has most likely the same stereochemistry as the L-hydroxyproline moiety that has been incorporated in the inhibitors described in section 5.1 (Figures 5.4 and 5.5).

In continuation, comparison of inhibitors incorporating the smallest P1 amino acid 8{1} with inhibitors incorporating the homoanalog 8{2} indicates that the extension of one carbon atom in the P1 position increases the activity roughly four times; this is exemplified by, for example, compounds 44{1,4} and 44{2,4} (280 and 67 nM, respectively). Inhibitors containing the vinylcyclopropyl amine 8{3} in the P1 position exhibit dramatically improved activity, which is demonstrated by comparison of, for instance, 44a{2,3} and 44a{3,3} (30 and 1.1 nM, respectively). In the P3/P4 position, the S,S stereochemistry is preferred for all reported inhibitors using the P2 hydroxyproline building block. Although this is true for those inhibitors, the novel P2 cyclopentene scaffold presented in our studies introduces a reversal of direction of the peptide chain at the P2 position, which results in inhibitors with two carboxy termini and also introduces a one-carbon extension along the P3/P4 amino acid chain. It might be expected that addition of a retro proline mimic at P2 would reverse the S,S stereochemical preference at P3/P4. However, the one-atom extension should again reverse the preference back to S,S. By comparing the 2D-structures of 1 and 44a{3,4}, it seemed likely that the S,S stereochemistry would be more favorable (Figure 1B and 1D), and this hypothesis was supported by a 3D computer overlay analysis. Further verification was provided by comparison of the activity of the P3/P4 R,R-derivative with that of the corresponding S,S-derivative, which made it evident that the S,S-derivative 44{1,2} (Ki 523 nM) indeed was more potent then the R,R-derivative 44a{1,1} (Ki >2000 nM). The S3 pocket is considered to be relatively small, but, despite that, the activity was enhanced when a valine was replaced with a tert-butyl glycine moiety in P3 (cf., 44a{2,2} and 44a{2,3}, 102 and 30 nM, respectively). It is possible that even bulkier P3 groups would further improve the activity. The interaction with the S4 pocket is very important for activity, as exemplified by the P1–P3 derivative 44{1,6} (> 2000 nM) and the P1–P4 derivative 44{1,2} (523 nM).
<table>
<thead>
<tr>
<th>Compd</th>
<th>Structure</th>
<th>$K_i$ (nM)</th>
<th>Compd</th>
<th>Structure</th>
<th>$K_i$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$44a{1,1}$</td>
<td><img src="image1" alt="Structure" /></td>
<td>$&gt;2000$</td>
<td>$44a{3,3}$</td>
<td><img src="image2" alt="Structure" /></td>
<td>1.1</td>
</tr>
<tr>
<td>$44{1,2}$ (anti)</td>
<td><img src="image3" alt="Structure" /></td>
<td>523</td>
<td>$44a{3,4}$</td>
<td><img src="image4" alt="Structure" /></td>
<td>1.3</td>
</tr>
<tr>
<td>$44{1,3}$ (anti)</td>
<td><img src="image5" alt="Structure" /></td>
<td>503</td>
<td>$44{3,5}$ (anti)</td>
<td><img src="image6" alt="Structure" /></td>
<td>$&gt;5000$</td>
</tr>
<tr>
<td>$44{1,4}$ (anti)</td>
<td><img src="image7" alt="Structure" /></td>
<td>280</td>
<td>$44b{2,2}$</td>
<td><img src="image8" alt="Structure" /></td>
<td>2560</td>
</tr>
<tr>
<td>$44{1,6}$ (anti)</td>
<td><img src="image9" alt="Structure" /></td>
<td>$&gt;2000$</td>
<td>$44b{2,3}$</td>
<td><img src="image10" alt="Structure" /></td>
<td>$&gt;2000$</td>
</tr>
<tr>
<td>$44a{2,2}$</td>
<td><img src="image11" alt="Structure" /></td>
<td>102</td>
<td>$44b{3,3}$</td>
<td><img src="image12" alt="Structure" /></td>
<td>108</td>
</tr>
<tr>
<td>$44a{2,3}$</td>
<td><img src="image13" alt="Structure" /></td>
<td>30</td>
<td>$44b{3,4}$</td>
<td><img src="image14" alt="Structure" /></td>
<td>23</td>
</tr>
<tr>
<td>$44{2,4}$ (anti)</td>
<td><img src="image15" alt="Structure" /></td>
<td>67</td>
<td>$56{3,3}$ (anti)</td>
<td><img src="image16" alt="Structure" /></td>
<td>$&gt;2000$</td>
</tr>
<tr>
<td>$44{3,2}$ (anti)</td>
<td><img src="image17" alt="Structure" /></td>
<td>24</td>
<td>$56{3,4}$ (anti)</td>
<td><img src="image18" alt="Structure" /></td>
<td>$&gt;2000$</td>
</tr>
</tbody>
</table>

Table 5.2. Activity data on target compounds.
free carboxylic acid in the P1 position is essential for HCV NS3 protease inhibitory properties, which can be compared with, for example, the acid $44a\{3,4\}$ (1.3 nM) and the tert-butylester $13\{3,4\}$, the latter of which is devoid of all activity. As previously reported, the carboxylic acid of the inhibitor probably forms hydrogen bonds with Ser139 in the catalytic triad of the protease. The methyl ester derivative $44a\{3,3\}$ (1.1 nM) and the methyl amide derivative $44a\{3,4\}$ (1.3 nM) are virtually equipotent, which suggests that a hydrogen-donating bond is not required at this position. In contrast, $N$-methylation of the P4NH derivative $44a\{3,4\}$ (1.3 nM) to give the P4NMe derivative $44\{3,5\}$ (> 5000 nM) resulted in a dramatical loss of inhibitory activity, suggesting that the P4NH is involved in a hydrogen bond network with the NS3 enzyme.

5.6 Conclusions

In the present work, a novel synthetic route was developed to the hydroxyproline bioisostere $50$, and the regio and stereochemistry of this scaffold was confirmed by NOESY and HMBC spectra. The scaffold $50$ was derivatized with various amines and the quinoline 7-methoxy-2-phenyl-quinolin-4-ol, which yielded the final products in series $44$. The stereochemistry of products $44a\{2,3\}$ and $44b\{2,3\}$ was verified by recording TOCSY and ROESY NMR spectra in combination with computer analysis. A total of eighteen inhibitors of the HCV NS3 protease were synthesized in the series $56, 44a,$ and $44b$, and the most potent of these has an impressive Ki of 1.1 nM (Table 5.2). The SAR data obtained should provide a useful tool in future projects focused on scaffold hopping.
6 Acknowledgments

I would like to thank the following people:

Professor Ingemar Kvarnström (University of Linköping) for being an excellent supervisor and for stopping me when I got carried away in matters concerning synthesis and writing.
Professor Bertil Samuelsson (Medivir AB) for never-ending ideas about how to improve syntheses and manuscript preparation.
Dr. Ingemar Nilsson (AstraZeneca R&D, Mölndal) for providing professional assistance with medicinal chemistry, both in the writing of papers and at meetings.
Dr. Åsa Rosenquist (Medivir AB) for improvement of manuscripts and practical advice.

AstraZeneca R&D, Mölndal, for financial support, and the following people who work at that facility:

Dr. Djordje Musil for spending his nonexistent sparetime on the X-ray structure of 14\textsuperscript{14}, Dr. Karl-Erik Karlsson for time spent at the HRMS machine on my account, Dr. Shalini Andersson for letting Hanna Nelander be my personal chiral HPLC consultant, Hanna Nelander for performing the chiral separation of 44\textsuperscript{1}, Marléne Fredenwall and Peter Abrahamsson for practical help with synthesizing the combinatorial library reported in paper I, and Erika Gyzander and the Biochemistry Group for performing the biological tests reported in paper II.

Medivir AB for financial support, as well as the following people who work at that company:
Taitana Maltseva for recording excellent NMR spectra, Lotta Vrang and Elizabeth Hamelink and the biochemistry group for biological testings reported in papers III, and Hans Wallberg and Xiao-Xiong Zhou for good ideas at meetings.

Past and present colleagues in the Kvarnström group:

Per Ola Johansson for being an excellent wingman during our years of PhD studies together; Anders Dahlgren for practical help and all discussions about global issues and weird things; Jonas Brâñalt for sending chemistry articles to me and allowing me stay at “Hotel Balltorp”; Yantao Chen for sharing vital knowledge of Chinese culture (Kung Fu movies); Jonas Nilsson for being a friend and valuable sounding board; David Pyring and Nelly Bibak for sharing with me an office, vital knowledge, and nonsense; Marcus Bäck for helpfulness and for being the 747 man; Veronica Sandgren for being kind and cheerful; Fredrik Wångsell the heir to my office and my chair,—thanks for being a good roommate and chemist for the past two years.
My Master’s thesis students who have assisted me in my projects:

Patrick Johansson, Elisabet Palmqvist, Cecelia Andresen, Linda Karis
Fredrik Wångsell, Maria Wikberger, Maja Wiklund, Camilla Romanov,
Veronica Sandgren, Per-Olof Bergh, and Malek Mirzayan.

Good ol’ days, the early years (1999–2002):
Professor Uno Carlsson, Karin Carlsson, Magdalena Svensson, Malin Person, Per
Hammarström, Dick Andersson, and Martin Karlsson mainly for being there at
lunch time during my first years at the Department, but also for some enlightenment
regarding biochemistry and beer. Johan Ekerot, Jan Lundqvist, Jonas “Baltzer”
Nilsson, Anders Dahlgren, Daniel Nöteberg, Jonas Nilsson, Per-Ola Johansson,
Jonas Brånalt, Yantao Chen and Joakim Svensson for all the corridor conversations
and after-work activities.

The new deal, the present day (2003–2005):
Markus Hederos, Andreas Åslund, Per-Ola Johansson, Fredrik Wångsell,
Marcus Bäck, Timmy Fyrner, Patrik Nygren, Johan Viljanen, Tysken (Janosch)
and the quisling Johan Olson who went to Stockholm. The Vallfarten lunch troika
over the last two years—I want to thank them for all the coffee and other beverages
we have drunk together, all the rock concerts we went to, and for making the organic
chemistry corridor a cozy place to be.

Patricia Ödman for linguistic help with this thesis. Anders Hallberg for help with
manuscripts.

Mina föräldrar, Inger och Sören Thorstensson, för stöd, omtanke och visad förståelse och
min bror, Frank Thorstensson, för att han aldrig ger upp och för att han är min bror.

Anngelica Jarl—Tack för att du finns och står ut med mig.
7 References

(1) B. Jönsson, Intervju med Dr. Jan Lundberg (head of discovery research, AstraZeneca). Kemist söker kemister, **2002, Kemivärlden**, 31-32.


(4) Bell, I. M.; Freidinger, R. M.; Guare, J. P.; Sparks, M. A.; Williams, P. D. 1999 **GB 02326639; US 5968938**.


(21) This article is important in the development of the D-Pro-Arg based inhibitors: Bajusz, S; Barabas, E.; Tolnay, P.; Szell, E; Bagdy, D. Inhibition of thrombin and trypsin by tripeptide aldehydes. *Int. J. Pept. Protein Res*. 1978, 12, 217-221.

(22) This article describes the X-ray of PPACK with alpha-thrombin, important starting point for the D-Phe-Pro-Arg inhibitors developed by AstraZeneca: Bode, W.; Mayr, I.; Baumann, U.; Uber, R.; Stone, S. R.; Hofsteenge, J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. *Embo. J.* 1989, 8, 3467-3475.


(48) (a) De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine


(61) Mitsunobu, O. Synthesis, 1981, 1


(68) Scanned spectra are included in supporting information for *paper III*.


(73) The (1R,2S)-1-amino-2-vinyl-cyclopropanecarboxylic acid ethyl ester was bought from Syngene-Custom Research, Bangalore, 20th KM Hosur Road, Electronics City, Bangalore 560100, India.


